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Abstract: A double side-reaction, consisting in the formation of Fmoc-β-Ala-OH and Fmoc- β-
Ala-AA-OH, during the preparation of Fmoc protected amino acids (Fmoc-AA-OH) with Fmoc-
OSu is discussed.  Furthermore, the new Fmoc-2-MBT reagent is proposed for avoiding these 
side-reactions as well as the formation of the Fmoc-dipeptides (Fmoc-AA-AA-OH) and even 
tripeptides, which is another important side-reaction  when chloroformates such as Fmoc-Cl is 
used for the protection of the α-amino function of the amino acids. 
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INTRODUCTION 
 
Carbamates such as Boc,1,2 Fmoc,3 Z,4 and in minor extension Alloc,5,6 pNZ,7 and 
Troc8 are the most efficient way to mask the nucleophilicity of the amino function 
during peptide synthesis.9,10  The introduction of the alkoxycarbonyl moiety was 
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first carried out under weakly basic conditions via the Schotten-Baumann reaction 
using the corresponding chloroformates (also known as chloride).3  However, our 
group11 and others12,13,14,15 described in the early eighties that during the preparation 
of Fmoc-amino acids from Fmoc-Cl, the most part of the amino acids maybe 
contaminated with significant levels (1-20%) of their corresponding Fmoc-
dipeptide and even tripeptide.   As an example, even when the relatively hindered 
Alloc-Val-OH was prepared in a laboratory scale, 14% of the corresponding 
dipeptide was obtained.9  This high incidence of protected dipeptide can lead to the 
insertion of an extra amino acid in the final peptide synthesis, which cannot be 
tolerated for the preparation of an API.  This side-reaction can be avoided by 
carrying out an in situ bis-trimethylsilylation protection followed by reaction with 
the chloride.14,16 The fact that the temporal protection of the carboxylic function 
avoids the side-reaction reinforces that the mechanism goes through a asymmetrical 
anhydride  (Figure 1).   
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Figure 1.  Mechanism for the formation of protected dipeptides during the 
protection of amino acids 
 
  As alternative to the chloride and as this side-reaction is associated to the quality 
of the leaving, we proposed the use of the less reactive azide derivative, which can 
be readily prepared and isolated from the chloroformate3,11 or prepared in situ 
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before reacting with the amino acid.17  Several approaches based in the use of others 
less reactive species such as the 1,2,2,2-tetrachloroethyl,18,19 the 5-norbornene-2,3-
dicarboximido,20 the pentafluorophenyl,21 and the symmetrical pyrocarbonates22 
have been proposed, but the hydroxysuccinimido (Su)12,13,15,23,24 ester has been 
considered the reagent of choice for the introduction of the protecting moiety.  
  However, lastly the use of Fmoc-OSu has been questioned, because it has been 
showed that commercial Fmoc-amino acids prepared from Fmoc-OSu contains 
Fmoc-β-Ala-OH and Fmoc-β-Ala-AA-OH as contaminants (0.1-0.4%).25 Although, 
these are tiny amounts, they are unacceptable in the manufacture of a drug 
substance.    
Herein, a discussion regarding the formation of this double side-reaction is carried 
out as well as an alternative for the preparation of protected amino acids free of side 
reactions.   
 
EXPERIMENTAL SECTION 
General 
2-MBT was obtained from ARIEL (City, Country). HPLC was performed on a reversed-phase 
C18 (4.6 × 150 mm, 5 µm) with a linear gradient of 0.045% TFA and 0.036% in CH3CN (from 0 
% to 100%) at a flow rate of 1.0 mL/min and detection of 220 nm.   
Fmoc-2-MBT    
MBT ·DCHA salt: 
To a solution of 2-MBT (5g, 29.9 mmol) in 250 mL of EtOAc, DCHA was added and 
the resulting suspension was stirred overnight. The precipitate obtained was isolated by 
filtration washed with ethyl acetate and dried in vacuo yielding a white solid (9.44 g, 
91% of yield). 
Fmoc-2-MBT: 
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To a solution of Fmoc-Cl (7.01g, 27.1 mmol) in 70 mL of CHCl3, MBT·DCHA salt 
(9.44 g, 27.1 mmol) was slowly added and stirred overnight. The suspension was 
filtered and the solid washed with 2 x 10 mL of CHCl3. The filtrate was washed with 
10% of aq. citric acid (2 x 30 mL), 10 % of aq. NaHCO3  (2 x 30 mL), H2O (2 x 30 
mL), dried over MgSO4 and evaporated to dryness to yield the title compound as a 
white solid (8.53 g, 81.9 % of yield). 
1H NMR (400 MHz, CDCl3): δ= 8.01 (d, 1H, J= 8.2 Hz), 7.85 (d, 1H, J= 8.0 Hz), 7.72 
(d, 2H Fmoc, J= 7.5 Hz), 7.53 (d, 2H Fmoc, J= 7.5 Hz), 7.47 (dd, 1H, J= 8.0 Hz, J’= 
7.4 Hz), 7.39 (m, 2H Fmoc and 1H MBT), 7.28 (dd, 2H Fmoc, J= 7.5 Hz, J’= 7.5 Hz), 
4.60 (d, 2H, J= 7.3 Hz), 4.27 (t, 1H, J= 7.3 Hz). 
13C NMR (100 MHz, CDCl3): δ= 166.47, 157.49, 152.40, 143.00, 141.53, 136.99, 
128.33, 127.53, 126.72, 125.99, 125.28, 123.47, 121.45, 120.40, 70.96, 46.78. 
Fmoc-amino acids using Fmoc-2-MBT  
Fmoc-glycine 
H-Gly-OH (318 mg, 4.24 mmol) was suspended in 24 mL of a mixture of 1% aquous 
Na2CO3-dioxane (1:1, v/v) and cooled with and ice bath. A mixture of Fmoc-MBT (1.5 
g, 3.85 mmol) and 4 mL of dioxane was slowly added keeping the pH at 9.5 with 10% 
aq. Na2CO3. The ice bath was removed and the suspension stirred at room 
temperature keeping the pH at 9.5. The course of the reaction was followed by TLC. 
After 24 h of stirring 50 mL of H2O were added to the reaction mixture, the pH was 
adjusted to 8 with 1N HCl and washings with MTBE (3 x 30mL) were carried out. The 
aq. phase was acidified to pH 1 with HCl-H2O (1:2) and  extracted with EtOAc (3 x 40 
mL). The organic fractions were dried with MgSO4, evaported to dryness and the 
resulting yellow solid was washed with DCM to give Fmoc-Gly (627 mg, 55% of yield, 
yield not optimized) as a white solid. The product was characterized by  HPLC and 
ESMS.  
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RESULTS AND DISCUSSION 
A possible explanation for the presence of this double side-reaction (formation Fmoc-β-
Ala-OH and Fmoc-β-Ala-AA-OH) are depicted in Figure 2.  One of the cornerstones of 
this process involves the presence of a nucleophile and herein two nucleophiles are 
present: -OSu and -OH.   
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Figure 2.  Mechanism for the formation of Fmoc-β-Ala-OH and Fmoc-β-Ala-AA-OH 
during the protection of amino acids 
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The β-Ala structure (1) was formed through a Lossen rearrangement after the attack of 
a nucleophile, probably –OSu, to one of the carbonyls of the HOSu moiety presented in 
the Fmoc-OSu. A similar pathway for this first part of the mechanism was first reported 
by during the reaction of HOSu with DCC,26 and then by Wilcheck and Miron.27 
Furthermore, similar β-Ala impurities have been found by Zalipsky during the use 
PEG-OSu as pegylation reagent.28  
The formation of the free amine of the β-alanine is coming from the carbamic acid 
(Nu2=OH, pathways b and c) or from the rather unstable O-N-succinimide carbamate 
(Nu2=Su, pathways a and d).  Furthermore, the formation of the Su ester of β-Ala (2), 
which is susceptible of reacting with the free amino acid to give the dipeptide, is 
formed when Nu1=Su (pathways a and b).  This mechanism also interprets the major 
content found by Hlebowicz et al.25 (Table 9, Arg) of β-Ala by amino acid analysis than 
those found by HPLC (Fmoc-β-Ala-Arg-OH + Fmoc-β-Ala-OH).  This higher amount 
can be interpreted from 2, which can give polymerization and therefore the 
corresponding peaks can be more difficult to be identified.  Furthermore, this scheme 
agrees with the no formation of Fmoc-AA-β-Ala-OH as pointed out by Hlebowicz et 
al.25    
Formation of H-β-Ala-OH or H-β-Ala-OSu can take place either during the preparation 
of Fmoc-OSu or during the preparation of the protected amino acids.  However, the 
HPLC analysis of commercial Fmoc-OSu has revealed the absence of Fmoc-β-Ala-OH 
and therefore indicated that the side-reaction is taking place during the protection of the 
amino acids.   
Thus, if a substitute to Fmoc-OSu wants to be found, this should be of a reactivity 
similar to OSu esters and therefore lower that other active species such as OBt, which 
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leads to the formation of protected peptides or tripeptides.12 In this regard, the 2-MBT 
recently proposed by Evans as additive to the carbodiimides based coupling in 
substitution of the HOBt called our attention.29  Thus, pKa calculations carried out with 
ChemAxon software showed that the pKa of both tautomers of 2-MBT (pKa’s: NH 
tautomer, 10.90; SH tautomer, 7.49) was higher than the one of  HOSu (pKa HOSu, 
7.19) making it 2-MBT derivatives potentially less reactive than OSu ones. 
One additional advantage of 2-MBT is the price as it is broadly used as ARIEL SOME 
INFORMATION?.  
N
S
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Figure 3. Structure of 2-MBT 
Preparation of Fmoc-2-MBT was readily achieved by reaction of 2-MBT with Fmoc-Cl 
following a well reported method described for another reagents.23  Although, in the 
literature is described that 2-MBT active species are presented in a mixed of S- and N-
regioisomers, the structure obtained by X-ray diffraction of the Fmoc-2-MBT showed 
to be just the S-regioisomer (Figure 4). 
 
Figure 4.  Structure of the Fmoc-2-MBT obtained by X-Ray 
Difraction. 
 
 Fmoc-2-MBT reacts smoothly with amino acids to render the corresponding Fmoc-
AA-OH.  It is worthy to indicate that the acylation reaction is slower when it is carried 
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out with Fmoc-2-MBt than when Fmoc-OSu is used (24 h vs 0.5 h to accomplish a total 
conversion).  This rather slow conversion indicates than 2-MBT active species are less 
reactive than OSu ones and therefore that the acylation presumably is taking place 
without the formation of Fmoc-dipeptides, because as it was discussed earlier, its 
formation is associated to the effectivity of the active specie.   The 2-MBT liberated 
during the reaction can be removed by washing the final product with DCM.  HPLC 
analysis of the crude Fmoc-amino acids obtained following this method showed that no 
formation of dipeptide took place and therefore that they are free of side-products 
(Figure 5), confirming the first hypothesis about the poor reactivity of the 2-MBT 
derivatives. 
 
Figure 5.  HPLC analysis: (a)  Fmoc-Gly-OH 
obtained, (b) Fmoc-Gly-Gly-OH, (c) coinjection 
of Fmoc-Gly-OH and Fmoc-Gly-Gly-OH. 
 
 
CONCLUSIONS 
The use of the new Fmoc-2-MBT reagent allows the preparation of Fmoc-amino 
acids free of the three side-products:  (a) Fmoc-dipeptides associated to the quality 
of the leaving group and that takes place when Fmoc-Cl is used; (b) Fmoc-β-Ala-
OH; and (c) Fmoc-β-Ala-AA-OH. These two side-products is produced when 
Fmoc-OSu is used as acylating reagent.  A mechanism for the presence of the side-
products has been also proposed.  
This study was partially supported by CICYT (CTQ2006-03794/BQU, PETRI), the 
Generalitat de Catalunya (2005SGR 00662), the Institute of Research in 
Biomedicine, and the Barcelona Science Park.  AI-L. thanks MEC (Spain) for a 
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ABBREVIATIONS 
Abbreviations used for amino acids and the designations of peptides follow the IUPAC-
IUB Commission of Biochemical Nomenclature in J. Biol. Chem. 1982, 247, 977−983. 
Amino acid symbols denote L-configuration. 
API, active pharmaceutical ingredient; Alloc, allyloxycarbonyl; Boc, tert-
butyloxycarbonyl; DCC, N,N’-dicyclohexylcarbodiimide; DCHA, 
dicyclohexylamine; DCM, dichloromethane; EtOAc, ethyl acetate, ESMS, 
electrospray mass spectrometry; Fmoc, 9-fluorenylmethoxycarbonyl; HOBt, 
hydroxybenzotriazole; HPLC, high performance liquid chromatography; 2-MBT, 2-
mercaptobenzothiazole; MTBE, tert-butylmehtyl ether; OSu, O-succinimidyl; PEG, 
polyethylene glycol; polystyrene solid support; pNZ, p-nitrobenzyloxycarbonyl; 
SPPS, solid-phase peptide synthesis; TFA, trifluoroacetic acid; Z, 
benzyloxycarbonyl; Troc, 2,2,2-Trichloroethyloxycarbonyl. 
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